BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Thalassemia clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for thalassemia: 44 (22 sponsors; 0 newly posted in the last 180 days, 3 stopped in the last 180 days; 0 new-entrant sponsors). Momentum score 8, rank 80 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 4, Phase 1 3, Phase 2 14, Phase 3 9, Phase 4 3, N/A 11.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Agios Pharmaceuticals, Inc. AGIO6P4 1, P3 4, P2 100
Vertex Pharmaceuticals Incorporated VERX3P3 300
Celgene2P2 1, P3 100
Novo Nordisk A/S NVO1P3 100
Bristol-Myers Squibb BMY5P2 2, NA 2, P4 100
CorrectSequence Therapeutics Co., Ltd4P2 1, NA 2, EARLY_P1 100
Shenzhen Hemogen4EARLY_P1 3, P1 101
Bioray Laboratories3NA 2, P2 100
Editas Medicine, Inc. EDIT2NA 1, P2 100
Genetix Biotherapeutics Inc.2NA 200
Elpen Pharmaceutical Co. Inc.1NA 100
Imara, Inc.1P2 100
Kanglin Biotechnology (Hangzhou) Co., Ltd.1P2 100
Kind Pharmaceuticals LLC1P2 101
Lantu Biopharma1P2 100
Mabwell (Shanghai) Bioscience Co., Ltd.1P1 100
Novartis Pharmaceuticals NVS1P4 100
Pharmacosmos A/S1P2 100
Regeneron Pharmaceuticals REGN1P2 101
Sangamo Therapeutics SGMOQ1NA 100
ScinnoHub Pharmaceutical Co., Ltd.1P2 101
Shanghai BDgene Co., Ltd.1P1 101

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2Kind Pharmaceuticals LLCNCT06302491 A Study of Safety and Efficiency of AND017 in Patients With β-thalassemiaβ -Thalassemiarecruiting64
2026-12-03 est.P2Regeneron Pharmaceuticals REGNNCT06421636 A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult ParticipantNon-Transfusion Dependent Beta-Thalassemia (NTDT)active not recruiting19

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-20 est.P1/P2Bioray LaboratoriesNCT05577312 Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-ThalassemiaBeta-Thalassemiaactive not recruiting39

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "thalassemia"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.